Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorPeking University First Hospital

About this trial

With aging population, more older patients will receive major surgery for cancer. Older patients are at increased risk of postoperative neurocognitive complications including delayed neurocognitive recovery (dNCR), which is associated with prolonged hospital stay, raised complications, and impaired quality of life. Intraoperative hypothermia occurs in 57.1%-78.6% of patients undergoing major cancer surgery, especially in the elderly. Studies show that intraoperative hypothermia suppresses immune function, interferes with anesthetic metabolism, and delays anesthesia emergence. All these may be correlated with the occurrence of early postoperative dNCR. This study aims to verify whether intraoperative targeted temperature management (target core temperature: 36.8°C) compared with conventional temperature management (core temperature: 35.5°C) can reduce the incidence of dNCR in older patients undergoing major cancer surgery.

Eligibility criteria

Qualifiers

Age ≥ 65 years.

Planned potentially curative initial cancer surgery with an expected duration of 2 hours or longer under general anesthesia.

Disqualifiers

Preoperative fever (tympanic temperature ≥ 38℃).

Known or suspected preoperative infection.

Previous schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or preexisting delirium.

Inability to communicate due to coma, severe dementia, or hearing or speech impairment.

Trial design

Treatments tested in this trial

  • Target temperature management
  • Routine thermal management

Treatment groups

1,512 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Peking University First Hospital

Lead sponsor

Peking University Shenzhen Hospital

Collaborator